EliA Tests Helping in the Diagnosis of Autoimmune Diseases

Autoimmune disorders are rare and difficult to diagnose. That’s why we have developed more than 57 clinically relevant tests manufactured to help healthcare providers make a better diagnosis and more informed treatment decisions. Our high-quality portfolio of markers comprises tools for the diagnosis of the most frequent systemic and organ-specific autoimmune diseases, including connective tissue diseases, rheumatoid arthritis, antiphospholipid syndrome, vasculitis and Goodpasture syndrome, inflammatory bowel disease, celiac disease, pernicious anemia, autoimmune liver diseases, and autoimmune thyroid diseases. We deliver extensive support that gives you the confidence your lab needs to provide a first-class autoimmunity diagnostic service that puts the patient first.1-6


Why choose Thermo Fisher Scientific as your partner in autoimmune disease diagnostics? 

Helping clinicians put the patient first with EliA tests. EliA™ tests provide a clinically relevant, accurate, and continuously growing autoimmune disease test portfolio on reliable laboratory systems with scalable instrument solutions for different throughput needs.

View all of our available products.
Visit Product Catalog
Looking for allergy testing?
View ImmunoCAP Allergy Tests

EliA tests assist you in putting the patient first by:

Helping your lab provide a comprehensive clinical picture. 

  • Offering one of the broadest portfolios on the market, consisting of clinically relevant markers developed into the highest quality tests to support in the diagnosis of autoimmune diseases, potentially improving patient outcomes.1

Helping you get it right the first time.

  • Focusing on the optimum balance of sensitivity and specificity, the EliA portfolio can help enable clinicians to diagnose the patient correctly, sooner.1-6


  • With best-in-class specificity in celiac disease and rheumatoid arthritis, EliA tests can help you reduce false positive results and avoidable treatments in these highly investigated conditions.2-4  

Driving workflow efficiency

EliA tests use ready-to-use reagents and an efficient, flexible calibration system with one calibration curve per method stored for 28 days (i.e., IgG, IgM, IgA, Calprotectin, and anti-TSH-R), allowing you to maximize workflow efficiency by:1

  • Loading and unloading tests as needed, enabling you to run low throughput tests as they arrive.1
  • Reducing costs and minimizing valuable time associated with managing calibration curves.1
  • Ensuring long walkaway times once the run has been started, supporting lean working.1

State-of-the-art tests: Simplifying laboratory operations

  • EliA tests are developed and manufactured in our center of excellence facility using the eukaryotic Sf9 expression system to produce recombinant antigens. This will help to simplify your laboratory operations through the efficient production of high-volume lots with excellent lot-to-lot reproducibility, maximum accuracy, and outstanding quality, ultimately reducing validation steps in your laboratory.1, 7



Hidden Button for Video to show in modal

Explore the full EliA portfolio.
View Portfolio
Find an instrument to run EliA tests.
View Phadia Laboratory Systems
Find helpful resources for your lab and your clients.
Visit Resource Library

These products may not be cleared for use in your country. Please contact your sales representative for information about specific product availability.

  1. Thermo Fisher Scientific. Data on file.  
  2. Werkstetter KJ, Korponay-Szabo IR, Popp A, Villanacci V, Salemme M, Heilig G, et al. Accuracy in Diagnosis of Celiac Disease Without Biopsies in Clinical Practice. Gastroenterology. 2017;153(4):924-35. 
  3. Mathsson Alm L, Fountain DL, Cadwell KK, Madrigal AM, Gallo G, Poorafshar M. The performance of anti-cyclic citrullinated peptide assays in diagnosing rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol. 2018;36(1):144-52.
  4. Mascialino B, Swiniarski S, Gehring I., Poorafshar M, Tarrant T. Serum Autoantibody Multi-Analyte Testing in Rheumatoid Arthritis Can Reduce Avoidable Costs Associated from False Positive Results. A Simulation Study in the United States of America. Presented at ACR Annual Meeting Chicago. 19-24 October 2018.  
  5. Robier C, Amouzadeh-Ghadikolai O, Stettin M, Reicht G. Comparison of the clinical utility of the Elia CTD Screen to indirect immunofluorescence on Hep-2 cells. Clin Chem Lab Med. 2016;54(8):1365-70.
  6. Willems P, De Langhe E, Claessens J, Westhovens R, Van Hoeyveld E, Poesen K, et al. Screening for connective tissue disease-associated antibodies by automated immunoassay. Clin Chem Lab Med. 2018;56(6):909-18.
  7. Schmitt J, Papisch W. Recombinant autoantigens. Autoimmun Rev. 2002;1(1-2):79-88